Candidate Compounds Covid19

Version vom 28. Juni 2020, 07:07 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

• reviews on covid drug development
• scouting ideas

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome colchicine
• Methotrexate
• other anti-inflammatory
• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• TGF beta
• Anticoagulant in covid19
• Antioxidants
• Stem cells
• MDSC cells
• Interferons

• other single compounds
• Retargeted single compounds
• Hydroxychloroquine
• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein any other covid targed herein
• other antiviral compounds
• AV Remdesivir
• AV Lopinavir
• AV Ivermectin
• AV Arabidol
• AV Favipiravir

• Vitamin D
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc
• Nutrition, general
• Exercise, Vibration

• Traditional Chinese Medicine
• Natural compounds

• Statins
• Antidiabetic compounds, any
• RSP - On RAS drugs

• Reconvalescent blood products, Passive vaccine
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Radiation therapy
• Phototherapy
• Active vaccine

008

32458400 2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.

32401611 2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.

32413736 2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.

32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.

32534188 2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.

32534094 2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).

32435920 2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?
32382873 2020. Covid-19 and drug therapy, what we learned.
32460369 2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.
32412158 2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
32531935 2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.

32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.

32425638 2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
32522597 2020. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients.
32502659 2020. Potential role of statins in COVID-19.
32521619 2020. Redox-Modulating Agents in the Treatment of Viral Infections.
32461554 2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.

32327922 2020. The 4 D's of Pellagra and Progress.
32447429 2020. Trials and tribulations: so many potential treatments, so few answers.
32483523 2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
32426222 2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.

32488835 2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.

32458206 2020. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?
32411575 2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.
32479759 2020. Successful use of methylprednisolone for treating severe COVID-19.
32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.

32527713 2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
32397940 2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors.

32396773 2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.

32396769 2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.
32394467 2020. A global treatments for coronaviruses including COVID-19.

32526460 2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.

32517353 2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
32425662 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.

32384202 2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.

32388906 2020. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?

32495299 2020. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?

32398164 2020. Drug repurposing against COVID-19: focus on anticancer agents.

32509284 2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.
32395245 2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?

32422152 2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.

32533263 2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.
32405780 2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.

32383582 2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.
32432466 2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.
32402186 2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
32428392 2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
32478500 2020. COVID-19 and Other Pandemics: How Might They Be Prevented?
32519842 2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
32469114 2020. An update on ACE2 amplification and its therapeutic potential.

32350686 2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
32454090 2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).
32534451 2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
32489694 2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?
32489692 2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.

32516203 2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
32406904 2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.

32479920 2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.

32310688 2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.
32315803 2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
32519894 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
32297590 2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
32499129 2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.

32505720 2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.
32534022 2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.

32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.

32489437 2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.
32513797 2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.
32440665 2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.

32493626 2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.

32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
32399096 2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.
32399095 2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.
32399094 2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction.
32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
32514689 2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.

32446195 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.

32399655 2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.
32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
32440566 2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.

32458149 2020. Can Zn Be a Critical Element in COVID-19 Treatment?
32532623 2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
32426388 2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.
32426387 2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32410772 2020. Emerging pharmacotherapies for COVID-19.

32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.

32383371 2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.
32508168 2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.
32401215 2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.

32410266 2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.

32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.

32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
32454981 2020. Current regulatory approaches for accessing potential COVID-19 therapies.
32468385 2020. Musings on the current state of COVID-19 modeling and reporting.
32435882 2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.

32406687 2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.

32452670 2020. Immunity-Boosting Spices and the Novel Coronavirus.
32525650 2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?
32534130 2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.

32525715 2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.
32396382 2020. Myth Busters: Dietary Supplements and COVID-19.
32523147 2020. Anotaciones breves sobre el sindrome de liberacion de citocinas y el bloqueo terapeutico de la interleucina-6 en SARS-CoV-2/COVID-19.
32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32518135 2020. Paediatric treatment trials for COVID-19 are an ethical imperative.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32515023 2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.

32533795 2020. Further aspects of doxycycline therapy in COVID-19.
32533990 2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?
32529218 2020. Statin therapy in COVID-19 infection: much more than a single pathway.

32520031 2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.

32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.
32516380 2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.

32515404 2020. Comprehensive overview of COVID-19 clinical trials.
32515383 2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.

32395418 2020. An Update on Current Therapeutic Drugs Treating COVID-19.
32391242 2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.
32467020 2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
32425691 2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.
32385829 2020. COVID-19 and off label use of drugs: an ethical viewpoint.
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.

32418299 2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?
32406143 2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?

32390307 2020. Practical tips for using masks in the COVID-19 pandemic.
32358890 2020. Cutaneous side-effects of the potential COVID-19 drugs.

32428864 2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.

32514859 2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.

32451923 2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
32523611 2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.
32499832 2020. Pharmacological treatment of COVID-19: lights and shadows.
32520599 2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.

32469436 2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.
32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
32482569 2020. Nutricion Clinica en tiempos de COVID-19.
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
32379302 2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.

32518390 2020. Editorial: Nutrition and COVID-19.
32433599 2020. Nutritional management of COVID-19 patients in a rehabilitation unit.
32404899 2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.

32414641 2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.

32430428 2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
32398309 2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?

32398976 2020. siRNA could be a potential therapy for COVID-19.
32518634 2020. Lithium and coronaviral infections. A scoping review.
32518636 2020. A snapshot of the ongoing clinical research on COVID-19.
32395702 2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?

32426374 2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.

32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?
32390971 2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.
32468851 2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.
32406749 2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.
32406253 2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?
32523109 2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.

32501513 2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.
32433861 2020. How to Discover Antiviral Drugs Quickly.
32515974 2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.

32514101 2020. First antibody against COVID-19 spike protein enters phase I.

32529963 2020. Can lactoferrin boost human immunity against COVID-19?
32535509 2020. COVID-19, interferons, and depression: A commentary.
32409452 2020. Pandemic could add noise to clinical trial data.

32527823 2020. Aggregating data from COVID-19 trials.
32527819 2020. Can existing live vaccines prevent COVID-19?

32520641 2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.
32520639 2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".

32470338 2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32427166 2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.

007

32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.

32476308 2020. Empirical Treatment and Prevention of COVID-19.
32466136 2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.

32486229 2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.
32481690 2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.
32471278 2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32429099 2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32392184 2020. Clinical trials for COVID-19 should include sex as a variable.

32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?

32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.
32293020 2020. Palliativ farmakologisk behandling vid svar covid-19.
32444382 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
32442946 2020. inverted question markBCG versus COVID-19?

32162896 2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.

32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.

32408547 2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
32486364 2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.

32486488 2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.

32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?

32423024 2020. The Rationale for Potential Pharmacotherapy of COVID-19.
32434254 2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.

32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.

32381590 2020. Ethics of controlled human infection to address COVID-19.

32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.

32395792 2020. COVID-19: Main therapeutic options.
32507409 2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.

32486283 2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
32397643 2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.

32485102 2020. Current Perspective of Antiviral Strategies against COVID-19.
32369098 2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
32398377 2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.

32462848 2020. Interleukine-1 et blocage du COVID-19.
32495979 2020. Emergence of novel coronavirus and progress toward treatment and vaccine.

32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.

32433189 2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.

32473596 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

32391659 2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].

32057209 2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].
32397700 2020. [Analysis of application of herd immunity as a control strategy for COVID-19].

32473600 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.
32490731 2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.

32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
32496239 2020. Potential pharmacological agents for COVID-19.

32496237 2020. AYUSH for COVID-19: Science or Superstition?
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.

32510105 2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.

32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.

32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.

32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.

32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.

32442323 2020. Curcumin as a potential treatment for COVID-19.
32430996 2020. Potential effects of curcumin in the treatment of COVID-19 infection.

32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

32492211 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.

32492205 2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.

32421836 2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.

32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.
32427277 2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
32495940 2020. Probiotics and COVID-19: is there any link?
32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
32505910 2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.
32502901 2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.

32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.

32369285 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369284 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369283 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369282 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369281 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
32325475 2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.

32393915 2020. Biggest COVID-19 trial tests repurposed drugs first.
32417850 2020. Drug researchers pursue new lines of attack against COVID-19.
32415300 2020. Biotech companies prepare for COVID-19 downturn.
32415251 2020. 15 drugs being tested to treat COVID-19 and how they would work.

32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
32415276 2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.
32409766 2020. Dozens of coronavirus drugs are in development - what happens next?
32405023 2020. Coronavirus drugs trials must get bigger and more collaborative.

32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.
32504019 2020. The coronavirus outbreak could make it quicker and easier to trial drugs.
32424192 2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.

32324361 2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]

32398330 2020. A Call for Pediatric COVID-19 Clinical Trials.
32423342 2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
32393419 2020. Recent advances of therapeutic targets and potential drugs of COVID-19.

32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.
32501634 2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?
32488956 2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?

32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?

32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.

32385052 2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
32381697 2020. The race is on for antibodies that stop the new coronavirus.
32381692 2020. Combination prevention for COVID-19.
32461212 2020. Reducing transmission of SARS-CoV-2.
32385101 2020. Rapid repurposing of drugs for COVID-19.
32327575 2020. NIH organizes hunt for drugs.

32409433 2020. Antivirals for COVID-19.

32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.

32438473 2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.

32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.

32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.

32448085 2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.

32431217 2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.

32469418 2020. Evaluation of potential therapeutic options for COVID-19.

32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
32437001 2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".

32472779 2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?
32508069 2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.
32470199 2020. Metformin use amid coronavirus disease 2019 pandemic.

32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
32458475 2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.

32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

32437019 2020. Baricitinib: A chance to treat COVID-19?

32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.

32428941 2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

32449669 2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.

32495917 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.

32427004 2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
32452701 2020. An up-to-date overview of computational polypharmacology in modern drug discovery.

32447996 2020. Treatments in the COVID-19 pandemic: an update on clinical trials.
32475183 2020. Does lopinavir measure up in the treatment of COVID-19?

32282262 2020. Treatment considerations for coronavirus (COVID-19).
32469280 2020. COVID-19: Gene Transfer to the Rescue?
32423245 2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.
32212981 2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.
32501133 2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?
32503817 2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.

32503814 2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32468014 2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).

32310670 2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.

32443151 2020. Lopinavir pharmacokinetics in COVID-19 patients.
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
32469279 2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.

32462988 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).

32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.
32462970 2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.

32462996 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.

32476574 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.
32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.

32433345 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.

32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32473010 2020. TPE-nAbs combination therapy for severe COVID-19.
32220033 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).

32511912 2020. COVID-19: Drug targets and potential treatments.
32469301 2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.

32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.
32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.
32364561 2020. Randomized Clinical Trials and COVID-19: Managing Expectations.
32463427 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.
32453363 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.

32506195 2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.

32463794 2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.

32434272 2020. COVID-19Clinical trials: quality matters more than quantity.

32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32505821 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.

32455629 2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.

32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.

32454500 2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.
32453693 2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
32453692 2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.

32267762 2020. Research towards treating COVID-19.

32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32441783 2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
32424836 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
32445484 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.
32438446 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
32441462 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.
32511867 2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.
32418327 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.

32420947 2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).
32420936 2020. Treatments for COVID-19: emerging drugs against the coronavirus.
32425152 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
32506621 2020. Drugs being investigated for children with COVID-19.

32423954 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.

32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.

32510142 2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
32407491 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.

32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32345591 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.
32303505 2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.

32480418 2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.

32498751 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.

32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
32503806 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
32474583 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.
32459003 2020. A role for retinoids in the treatment of COVID-19?

32459832 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.

32498131 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.

32350861 2020. COVID-19: A Defining Moment for Clinical Pharmacology?
32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.

32212378 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.

32284037 2020. Perspective on the COVID-19 Coronavirus Outbreak.
32174284 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.
32400323 2020. In vitro data of current therapies for SARS-CoV-2.
32427000 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.

32416679 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
32394841 2020. COVID-19: An Update on Clinical Trials.
32282303 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help?
32510734 2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32419517 2020. Emerging therapies for COVID-19 pneumonia.
32429703 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
32419524 2020. Old and re-purposed drugs for the treatment of COVID-19.
32223349 2020. How could artificial intelligence aid in the fight against coronavirus?

32500928 2020. COVID-19 breakthroughs: separating fact from fiction.

32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

32401673 2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.

32428965 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.
32479158 2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
32437628 2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?

32446312 2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
32503855 2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.

32340978 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. -rest-
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro